Laurus Labs Registers Revenue Record

Company Sees Opportunities In US Generics Space

India’s Laurus Labs reported a strong fourth quarter and financial year on the back of a COVID-19 related demand surge. The company expects the growth rate to continue and improve in the coming quarters.

Revenue
Laurus Labs has seen its best quarterly and annual results • Source: Shutterstock

Laurus Labs has reported unprecedented growth for its fourth quarter and financial year ended March 2020, specifically for its generics business. While the company’s generic formulations business saw higher sales from low- and middle-income country tenders, contributing almost 30% of total revenue for the year that grew by 24% to INR28.32bn ($372m), its anti-viral offering in the generic active pharmaceutical ingredient segment also saw “stable revenues” and showed “robust growth.”

The anti-viral API revenues grew on a sequential basis for Laurus. “We expect this business to achieve stable revenues in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business